Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
paclitaxel
Norton Healthcare Ltd.
L01CD01
paclitaxel
Antineoplastic agents
Sarcoma, Kaposi; Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Breast Neoplasms
Paxene is indicated for the treatment of patients with:• advanced AIDS-related Kaposi's sarcoma (AIDS-KS) who have failed prior liposomal anthracycline therapy;• metastatic carcinoma of the breast (MBC) who have failed, or are not candidates for standard anthracycline-containing therapy;• advanced carcinoma of the ovary (AOC) or with residual disease (> 1 cm) after initial laparotomy, in combination with cisplatin as first-line treatment;• metastatic carcinoma of the ovary (MOC) after failure of platinum-containing combination therapy without taxanes as second-line treatment;• non-small cell lung carcinoma (NSCLC) who are not candidates for potentially curative surgery and/or radiation therapy, in combination with cisplatin. Limited efficacy data supports this indication (see section 5.1).
Revision: 14
Withdrawn
1999-07-19
B. PACKAGE LEAFLET 32 Medicinal product no longer authorised PACKAGE LEAFLET: INFORMATION FOR THE USER PAXENE 6 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION Paclitaxel READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE: - Keep this leaflet safe as you may need to read it again. - If you have further questions, please ask your doctor or your pharmacist. - This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Paxene is and what it is used for 2. Before you use Paxene 3. How to use Paxene 4. Possible side effects 5 How to store Paxene 6. Further information 1. WHAT PAXENE IS AND WHAT IT IS USED FOR Paxene belongs to a group of medicines known as antineoplastic agents. These agents are used to treat cancer. _ _ Paxene concentrate for solution for infusion is used to treat: • Advanced AIDS-related Kaposi’s sarcoma when certain other treatments (liposomal anthracyclines) have been tried but have not worked. This is a tumour that arises from blood vessels in the skin or internal organs and typically appears as flat or raised, purple to dark brown patches on the skin. • Advanced breast cancer when certain other treatments (standard anthracycline-containing therapy) have been tried but have not worked or when the patient is unsuitable for these treatments. • Advanced ovarian cancer or remaining tumour (> 1 cm) after initial surgery, in combination with cisplatin as first-line treatment. • Advanced ovarian cancer when certain other treatments (platinum-containing combination therapy without taxanes) have been tried but have not worked (as second-line treatment). • Advanced non-small cell lung cancer if potentially curative surgery and/or radiation therapy are not possible, in combination with cisplatin. There is limited inf Aqra d-dokument sħiħ
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 1. NAME OF THE MEDICINAL PRODUCT Paxene 6 mg/ml concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains 6 mg/ml of paclitaxel (30 mg of paclitaxel in 5 ml or 100 mg of paclitaxel in 16.7 ml or 150 mg of paclitaxel in 25 ml or 300 mg of paclitaxel in 50 ml). Excipients One vial contains polyoxyl castor oil: 527 mg/ml and ethanol anhydrous; 49.7 v/v% For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, colourless to slightly yellow, viscous solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Paxene is indicated for the treatment of patients with: – advanced AIDS-related Kaposi’s sarcoma (AIDS-KS) who have failed prior liposomal anthracycline therapy; – metastatic carcinoma of the breast (MBC) who have failed, or are not candidates for standard anthracycline-containing therapy; – advanced carcinoma of the ovary (AOC) or with residual disease ( > 1 cm) after initial laparotomy, in combination with cisplatin as first-line treatment; – metastatic carcinoma of the ovary (MOC) after failure of platinum-containing combination therapy without taxanes as second-line treatment; – non-small cell lung carcinoma (NSCLC) who are not candidates for potentially curative surgery and/or radiation therapy, in combination with cisplatin. Limited efficacy data supports this indication (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Paxene should only be administered under the supervision of a qualified oncologist in units specialised in the administration of cytotoxic agents (see section 6.6). All patients must be pre-medicated with corticosteroids, antihistamines and H 2 antagonists prior to Paxene. The following is a recommended pre-medication regimen: dexamethasone (8 - 20 mg) given orally (12 and 6 hours) or intravenously (30 - 60 mins) prior to Paxene, chlorpheniramine 10 mg intravenously or an equivalent ant Aqra d-dokument sħiħ